Difference between revisions of "Malignant peritoneal mesothelioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.ncbi.nlm.nih.gov/pubmed/" to "https://pubmed.ncbi.nlm.nih.gov/") |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|meso}} |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 11: | Line 11: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
==EURACAN/PSOGI== | ==EURACAN/PSOGI== | ||
| − | *'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] | + | *'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/32209311 PubMed] |
| − | ==[https://www.nccn.org/ NCCN] | + | |
| − | *[https:// | + | ==NCCN== |
| + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1513 NCCN Guidelines - Mesothelioma: Peritoneal] | ||
| + | **'''2023:''' Ettinger et al. [https://doi.org/10.6004/Jnccn.2023.0045 Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/37673108/ PubMed] | ||
| + | |||
=Advanced or metastatic disease, subsequent lines of therapy= | =Advanced or metastatic disease, subsequent lines of therapy= | ||
==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ||
| Line 37: | Line 41: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] [https://clinicaltrials.gov/ | + | #'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] [https://clinicaltrials.gov/study/NCT03074513 NCT03074513] |
[[Category:Malignant peritoneal mesothelioma regimens]] | [[Category:Malignant peritoneal mesothelioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] | ||
[[Category:Mesotheliomas]] | [[Category:Mesotheliomas]] | ||
Revision as of 11:59, 6 July 2024
| Section editor | |
|---|---|
 |
Marjorie G. Zauderer, MD, MS, FACP Memorial Sloan Kettering Cancer Center New York, NY, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
EURACAN/PSOGI
- 2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up PubMed
NCCN
Advanced or metastatic disease, subsequent lines of therapy
Atezolizumab & Bevacizumab
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Raghav et al. 2021 (MDACC 2016-0861) | 2017-2019 | Phase 2 |
Immunotherapy
- Atezolizumab (Tecentriq) 1200 mg IV once on day 1
Targeted therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03074513